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Decreasing drug development timeline via upstream process intensification 
A scalable, high-intensity perfusion process was developed at Boehringer Ingelheim, Fremont Inc which is 10x 
more productive for producing recombinant proteins than comparative fed batch processes in the same 14-day 
run duration. By eliminating wasteful cell bleed we were able to achieve cell densities up to five times greater 
than standard “steady state” perfusion culture previously used. In order to sustain such large cell masses at 
manageable media exchange rates, concentrated media feeds were developed which effectively allow for 
optimization of nutrient delivery and dilution rate. We believe this system is scalable up to 1kL; the process has 
already been demonstrated successfully at the pilot scale (100L), where bioreactor productivities averaging over 
5 g/L/day have been demonstrated.  
 
We begin development with new cell lines for the high intensity perfusion process by adapting spin-tube and 
shake flask models that others have used for fed batch. These methods are used to test for important control 
parameters to allow full development in a 2L bioreactor. AMBR250 bioreactors can be used, though not optimal, 
as will be discussed.  Due to the simplicity of the process design, the integrated downstream is developed at 
small scale using classical batch chromatographic techniques, including high throughput process development 
and standard chromatographic steps.  The virus inactivation step is developed by accounting for viscosity and 
titration of the product and buffer in the Protein A elution peak, which differ slightly from product to product. 
With these simple development techniques, we believe the highly productive process could be commercially 
viable at Phase I, with limited to no Phase III process development. 
 
 
 
 
